EU says global anti-counterfeit deal is close

Published 10/01/2010, 07:49 PM
Updated 10/01/2010, 07:52 PM

* Negotiators fail to reach anti-counterfeit accord in Tokyo

* EU officials say final deal just weeks away

* EU, U.S. still divided over scope of IPR protection

By Juliane von Reppert-Bismarck

BRUSSELS, Oct 2 (Reuters) - Negotiators for an international anti-counterfeit accord failed to reach agreement after more than a week of talks on Saturday, but EU officials said a final deal was just weeks away.

Differences between the EU and United States over how strict new intellectual property rules should be mean the negotiators trying to finalise the Anti-Counterfeit Trade Agreement will have to return to their capitals with only a draft accord.

"We've come a long way but we must still close the remaining gaps without which there will be no agreement," said a senior European Union official close to the negotiations.

The talks have pitted the United States against the EU since they began, with the EU demanding broad protection for its traditional food names like Parmesan cheese as well as for its fashion and car designs.

The United States and some other countries appealed for a narrower agreement that would protect mainly copyright and trademarks, whose violation has ravaged profits in the U.S. entertainment industry.

DIFFERENCES REMAIN

Differences now remain over the EU's demands for protection of food place names and a U.S. demand that individuals breaching patent law should not be prosecuted at home under either criminal or civil litigation, the EU official said.

But negotiators had come closer to a deal than they had expected, said the official, who declined to be named.

"EU Trade Commissioner (Karel) De Gucht welcomes the significant progress made in Tokyo on the ACTA agreement and believes the remaining elements can now be worked upon over the coming weeks," said EU spokesman John Clancy.

The EU has agreed that patent protection should not apply to goods in transit between countries.

This may go some way to reassuring pact critics, who say it could disrupt trade in legitimate generic drugs going to poor nations by allowing seizures of the products when in transit in participating countries, something that has occurred in the EU.

The talks involve the United States, the European Union and its 27 member states, Australia, Canada, Japan, New Zealand, Singapore, South Korea and Switzerland, and two developing countries -- Morocco and Mexico.

The countries said last month they planned to finish work in September and publish the final text of the agreement before deciding to finally sign it. [ID:nN20164161]

Participants in the talks have said they hope large trading nations such as China, India and Brazil will eventually join the pact.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.